Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma-Prevalence, Clinicopathological Variables, and Clinical Outcomes.
diabetes mellitus
oncology
pancreatic cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Jun 2022
08 Jun 2022
Historique:
received:
25
04
2022
revised:
26
05
2022
accepted:
05
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
pancreatic ductal adenocarcinoma (PDAC) is the seventh leading cause of cancer-related deaths with increasing incidence and link to the onset of diabetes mellitus (DM). The aim of this study is to describe the prevalence of DM among patients with the diagnosis of PDAC, analyse the association between the occurrence of DM and clinicopathological factors, and detect variables influencing overall survival. a retrospective analysis of medical records was performed. The patients were divided into non-DM ( Patients in the groups of DM and NODM had significantly longer median OS than the non-DM group. Nodal involvement, tumour location, level of CEA, CRP and CRP/lymphocytes ratio were significantly associated with OS among patients with any type of DM. Neutropenia was less frequently observed in the DM group. DM is prevalent among patients with pancreatic cancer. In our study, patients with DM receiving palliative chemotherapy had significantly higher median OS than those without DM. The increased comprehension of the mechanisms of the relationship between DM and pancreatic cancer needs further research, which might provide avenues for the development of novel preventive and therapeutic strategies.
Sections du résumé
BACKGROUND
BACKGROUND
pancreatic ductal adenocarcinoma (PDAC) is the seventh leading cause of cancer-related deaths with increasing incidence and link to the onset of diabetes mellitus (DM). The aim of this study is to describe the prevalence of DM among patients with the diagnosis of PDAC, analyse the association between the occurrence of DM and clinicopathological factors, and detect variables influencing overall survival.
METHODS
METHODS
a retrospective analysis of medical records was performed. The patients were divided into non-DM (
RESULTS
RESULTS
Patients in the groups of DM and NODM had significantly longer median OS than the non-DM group. Nodal involvement, tumour location, level of CEA, CRP and CRP/lymphocytes ratio were significantly associated with OS among patients with any type of DM. Neutropenia was less frequently observed in the DM group.
CONCLUSIONS
CONCLUSIONS
DM is prevalent among patients with pancreatic cancer. In our study, patients with DM receiving palliative chemotherapy had significantly higher median OS than those without DM. The increased comprehension of the mechanisms of the relationship between DM and pancreatic cancer needs further research, which might provide avenues for the development of novel preventive and therapeutic strategies.
Identifiants
pubmed: 35740504
pii: cancers14122840
doi: 10.3390/cancers14122840
pmc: PMC9221523
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Medical University of Warsaw
ID : PW/Z/1/1/20(1)
Références
N Engl J Med. 2010 Jan 14;362(2):129-37
pubmed: 20071702
Am J Cancer Res. 2020 Sep 01;10(9):2851-2864
pubmed: 33042621
Metabolism. 2011 Oct;60(10):1372-8
pubmed: 21550085
Cancers (Basel). 2021 Oct 18;13(20):
pubmed: 34680372
Oncotarget. 2015 Nov 3;6(34):36903-10
pubmed: 26372811
Mol Cancer. 2018 Jul 30;17(1):108
pubmed: 30060755
Nat Rev Mol Cell Biol. 2012 Mar 22;13(4):251-62
pubmed: 22436748
J Med Invest. 2021;68(3.4):244-255
pubmed: 34759138
Clin Gastroenterol Hepatol. 2021 May;19(5):876-884
pubmed: 32147593
J Surg Oncol. 2016 Feb;113(2):203-8
pubmed: 26799261
Cancer Metastasis Rev. 2021 Sep;40(3):865-878
pubmed: 34142285
Pancreatology. 2013 May-Jun;13(3):285-9
pubmed: 23719602
Endocr Pract. 2020 Jul;26(7):707-713
pubmed: 33471638
J Cancer Res Clin Oncol. 2013 Apr;139(4):681-9
pubmed: 23315099
Dig Dis Sci. 2018 Nov;63(11):2840-2852
pubmed: 30159732
Handb Clin Neurol. 2014;126:63-79
pubmed: 25410215
J Clin Oncol. 2015 Jan 1;33(1):29-35
pubmed: 25403204
Onco Targets Ther. 2016 Mar 22;9:1679-88
pubmed: 27042122
Cancer Manag Res. 2019 Sep 30;11:8781-8788
pubmed: 31632137
BMC Gastroenterol. 2019 Apr 24;19(1):59
pubmed: 31014264
Cancer Lett. 2017 Jan 28;385:225-233
pubmed: 27773749
Diabetes Care. 2010 Apr;33(4):931-9
pubmed: 20351229
Future Sci OA. 2018 Feb 21;4(4):FSO291
pubmed: 29682326
Nat Rev Dis Primers. 2016 Apr 21;2:16022
pubmed: 27158978
Diabetes Care. 2014 Jan;37 Suppl 1:S81-90
pubmed: 24357215
Cancers (Basel). 2021 Jan 16;13(2):
pubmed: 33467038
Surgery. 2014 Sep;156(3):591-600
pubmed: 25061003
Int J Cancer. 2010 Nov 15;127(10):2412-9
pubmed: 20143395
Am J Surg. 2015 Mar;209(3):564-9
pubmed: 25547091
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
JAMA. 2008 Dec 17;300(23):2754-64
pubmed: 19088353
JAMA. 2009 Oct 28;302(16):1752; author reply 1752-3
pubmed: 19861663
Int J Cancer. 2020 Dec 15;147(12):3384-3393
pubmed: 32580250
Int J Surg. 2018 Apr;52:342-346
pubmed: 29535016
Ann Surg Oncol. 2020 Oct;27(10):4017-4025
pubmed: 32144621
Sci Rep. 2015 Nov 24;5:17102
pubmed: 26598798
J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79
pubmed: 11307091
Cancer Med. 2012 Dec;1(3):357-62
pubmed: 23342285
Diabetes. 2017 May;66(5):1103-1110
pubmed: 28507210
World J Surg Oncol. 2021 Jun 21;19(1):182
pubmed: 34154596
J Surg Res. 2019 Jul;239:60-66
pubmed: 30802706
Nat Rev Cancer. 2013 Nov;13(11):759-71
pubmed: 24154716
Am J Cancer Res. 2015 Sep 15;5(10):3260-9
pubmed: 26693076
Expert Rev Anticancer Ther. 2019 Aug;19(8):681-687
pubmed: 31287962
Ann Surg Oncol. 2010 Feb;17(2):502-13
pubmed: 19885697
ESMO Open. 2021 Jun;6(3):100155
pubmed: 34020401
Tumori. 2021 Dec;107(6):550-555
pubmed: 33243068
Environ Toxicol. 2021 Aug;36(8):1491-1503
pubmed: 33886150
J Am Coll Surg. 2010 Apr;210(4):463-73
pubmed: 20347739
Onco Targets Ther. 2020 Oct 14;13:10417-10429
pubmed: 33116621
Mol Cancer. 2017 Jul 24;16(1):131
pubmed: 28738823
PLoS One. 2018 Jun 13;13(6):e0198938
pubmed: 29897998
N Engl J Med. 2010 Apr 29;362(17):1605-17
pubmed: 20427809
Diabet Med. 2006 May;23(5):469-80
pubmed: 16681555
Biochim Biophys Acta. 2015 Dec;1852(12):2706-11
pubmed: 26435083
Pancreatology. 2020 Jan;20(1):125-131
pubmed: 31706821
Ann Surg Oncol. 2017 Feb;24(2):561-568
pubmed: 27650825
Cancer Biol Ther. 2018;19(12):1153-1161
pubmed: 30067448
Int J Mol Sci. 2019 Feb 05;20(3):
pubmed: 30764482
Surgery. 2018 May 17;:
pubmed: 29779868
Biomarkers. 2021 Jun;26(4):325-334
pubmed: 33663300
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Cancer Chemother Pharmacol. 2016 Feb;77(2):235-42
pubmed: 26740120
Diabetes Metab Res Rev. 2012 Feb;28(2):169-76
pubmed: 22423386
World J Surg Oncol. 2012 Aug 24;10:171
pubmed: 22920886
Diabetes Metab Syndr Obes. 2020 Feb 19;13:463-476
pubmed: 32110079
Cancer Res Treat. 2016 Jan;48(1):171-9
pubmed: 25779362
Oncol Rep. 2009 Apr;21(4):1091-5
pubmed: 19288013